Sesen Bio, Inc. Banner Image

Sesen Bio, Inc.

  • Ticker SESN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Sesen Bio, Inc. Logo Image
  • 11-50 Employees
  • Based in Cambridge, Massachusetts
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicinium®, also known as VB4-845, is currently in a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2019, the Company initiated the BLA submissionMore for Vicinium to the FDA under Rolling Review. Vicinium is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
4.8 / 5.0 (161)

Sesen Bio, Inc. reports have an aggregate usefulness score of 4.8 based on 161 reviews.

Sesen Bio, Inc.

Most Recent Annual Report

Sesen Bio, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports

Sesen Bio, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!